Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias
Eslicarbazepine acetate, a third-generation antiepileptic drug (AED), has shown improved clinical response and safety in comparison to older generation AEDs for patients with partial-onset seizures. It is currently not known whether eslicarbazepine acetate is safe to use in patients with the acute h...
Main Authors: | Christopher D. Ma, Herbert L. Bonkovsky |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.953961/full |
Similar Items
-
Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
by: Christopher D. Ma, et al.
Published: (2022-12-01) -
Prophylactic Heme Arginate Infusion for Acute Intermittent Porphyria
by: Hung-Chou Kuo, et al.
Published: (2021-10-01) -
Acute porphyrias and porphyric neuropathy
by: Doungporn Ruthirago, et al.
Published: (2016-07-01) -
Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?
by: Charlotte Lawthom, et al.
Published: (2018-09-01) -
Eslicarbazepine acetate: An efficacy and safety as an antiepileptic drug in clinical trials and open studies
by: Martyna Stefaniak, et al.
Published: (2022-02-01)